Authors
Joud Hajjar, Bettzy Stephen, Ashley E Aaroe, Mazen M Aiche, Nagham Al-Zubidi, May Ameri, Kaitlyn E Aragon, Ivan Darin Carabenciov, Mark S Chambers, Amina Lateef Chaudhry, Jean M Connors, Michael A Davies, Kala Chand Debnath, Saadia A Faiz, Clifton D Fuller, Ryan P Goepfert, Dan S Gombos, Shruti Gupta, Matthew Hadfield, Katherine A Hutcheson, Shajedul Islam, Abdullah Jalal, Migara Jayasekera, Khalid A Jazieh, Aye Khine, Peter Kim, Stephen Y Lai, Yu Leo Lei, Yuanteng Jeff Li, Svetomir N Markovic, Holly McMillan, Amy C Moreno, Fiorinda Muhaj, Marc-Elie Nader, Adegbenga Otun, Omar Pacha, Nicolas L Palaskas, Anisha B Patel, Nimisha Patel, Zoe Quandt, Oded Sagiv, Elad Sharon, Malek Shatila, Ajay Sheshadri, Maria E Suarez-Almazor, Anusha Shirwaikar Thomas, Yinghong Wang, Alex Won, Hao Chi Zhang, Aung Naing
Published in
Journal of immunotherapy and precision oncology. Volume 9. Issue 4. Pages 153-245. Epub Sep 29, 2026.
Abstract
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their clinical impact is limited by immune-related adverse events (irAEs), therapeutic resistance, and the lack of reliable predictive biomarkers, contributing to a shift from early promise to a therapeutic plateau. irAEs affect multiple organ systems and may lead to treatment interruption and significant morbidity. Emerging strategies emphasize phenotype-driven and steroid-sparing approaches to control toxicity while preserving antitumor efficacy. Concurrently, primary and acquired resistance remain major challenges, driven by tumor-intrinsic mechanisms, immune microenvironment alterations, and host factors. Furthermore, current biomarkers, including programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden, demonstrate inconsistent predictive performance across tumor types. Advances in immune profiling, genomics, and microbiome research are enabling more precise patient stratification and informing novel therapeutic strategies, including rational combinations and targeted immunomodulation. This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability. Together, these advances position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
PMID:
42820064
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0